4Madaras-Kelly KJ, Ostergaard BE, Horde LB, et al. Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model[J].Antimicrob Agents Chemother, 1996, 40(3):627.
5Odenholt I, Lowdin E, Cars O. Pharmacodynamics of telithromycin In vitro against respiratory tract pathogens[J]. Antimicrob Agents Chemother, 2001,45(1): 23.
6Mingeot-Leclereq MP, Glupczynski Y, Tulkens PM. Aminoglycosides: aetivity and resistance[J]. Antimicrob Agents Chemother,1999,43(4) :727.
5Mainous AG 3rd, Hueaton WJ, Eberlein C. Colour of respiratorydischarge and antibiotic use[J], Lancet, 1997,350(9084) : 1077.
6Mainous AG 3rd, Macfarlane LL. Connor MK, et al. Survey ofclinical pharmacists, knowledge of appropriateness of antimicrobialtherapy forupper respiratory intentions and acute bronchitis [J].Pharmacotherapy,1999,19(4) :388-392.
7Alsobrook H. An overview of liability for drugs[J]. Drug Inf J,1992,26:317-328.
